#USA #Chicago #Lundbeck #bexicaserin #Vyepti

Introduction

Lundbeck, a prominent biopharmaceutical company dedicated to brain health, is poised to unveil new findings from its neurology portfolio at the American Academy of Neurology Annual Meeting 2026, set to take place from April 18 to 22 in Chicago. This year, Lundbeck will present seven research abstracts focusing on migraine, childhood-onset epilepsy, and multiple system atrophy (MSA). These presentations highlight Lundbeck's commitment to addressing critical gaps in the treatment of severe neurological disorders.

Research Highlights

One of the standout presentations will showcase Phase 1 safety and tolerability data for bocunebart (Lu AG09222), an innovative investigational monoclonal antibody aimed at migraine prevention. Unlike existing therapies that target the calcitonin gene-related peptide (CGRP) pathway, bocunebart targets pituitary adenylate cyclase-activating polypeptide (PACAP). This new approach could herald a change in migraine treatment, particularly for individuals who do not respond to current options.

Another significant focus will be the VYEPTI® (eptinezumab) studies. VYEPTI is a humanized monoclonal antibody developed for intravenous administration in migraine prevention. Lundbeck will share data from a Phase 3b clinical trial, including real-world evidence which examines its effectiveness among patients who have seen limited success with previous treatments. Notably, the findings from this study will discuss both headache-free periods and cognitive impacts, shedding light on quality of life for migraine sufferers.

Lundbeck is also making strides in childhood-onset epilepsy by presenting long-term findings related to bexicaserin, a selective 5-HT2C receptor superagonist under investigation for seizures in developmental and epileptic encephalopathies (DEEs). The open-label extension results from the Phase 1b/2a PACIFIC trial will be particularly enlightening, as they could pave the way for better therapeutic approaches in managing these severe epilepsy syndromes.

Additionally, findings regarding MSA will address clinical progression and the challenges in developing effective treatments for this rare neurodegenerative disorder. A consensus study will evaluate how outcomes can be expressed in a clinically meaningful way, thus improving understanding of disease management.

Lundbeck’s Commitment

Lundbeck's EVP and Head of Research & Development, Johan Luthman, remarked, "Neuroscience is reaching an inflection point, with new discoveries changing our approach to treatment. Our focus is to leverage these insights into drug development programs that not only validate mechanisms early but also prioritize areas with few existing treatment options."

The company's innovative drive reflects its dedication to evolving brain health treatments, especially for conditions like migraine and epilepsy where patient needs are underspecified. By participating in conferences like the AAN Annual Meeting, Lundbeck illustrates its determination to remain a forerunner in the neurology domain.

Conclusion

As Lundbeck presents its latest findings at the AAN 2026, attendees will witness a concerted effort to transform treatments for pressing neurological issues through research and innovation. The insights shared not only highlight Lundbeck's robust pipeline but also its unwavering focus on improving patient outcomes in areas of significant unmet medical need. With an emphasis on a biology-driven approach, Lundbeck is making strides that may redefine standards of care in neurology.

About Lundbeck
Founded over 70 years ago, Lundbeck has focused solely on brain health, developing transformative medications for neurological and psychiatric disorders. With a commitment to advancing research and addressing health equity, Lundbeck is at the forefront of enhancing the quality of life for patients worldwide.

For more information about Lundbeck's ongoing projects and presentations, visit Lundbeck's official website.